The pharmaceutical industry’s investment in Finland totalled 220 million euros ($250 million) in 2015, the domestic trade group has said.
Pharma Industry Finland (PIF) reported that the spending was mainly on research and development, and there was also investment in production.
The group is keen to promote Finland as a good place for clinical trials and to publicize the improvement in recent years in conditions for biobank and other register-based research, which uses data collected from biobanks and other healthcare registers. It anticipates an increase in research of this type in the Scandinavian country.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze